U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H53N2O4
Molecular Weight 529.7742
Optical Activity UNSPECIFIED
Defined Stereocenters 10 / 10
E/Z Centers 0
Charge 1

SHOW SMILES / InChI
Structure of ROCURONIUM

SMILES

[H][C@@]12C[C@@H]([C@H](OC(C)=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC[C@@]4([H])C[C@H](O)[C@H](C[C@]34C)N5CCOCC5)[N+]6(CC=C)CCCC6

InChI

InChIKey=YXRDKMPIGHSVRX-OOJCLDBCSA-N
InChI=1S/C32H53N2O4/c1-5-14-34(15-6-7-16-34)28-20-26-24-9-8-23-19-29(36)27(33-12-17-37-18-13-33)21-32(23,4)25(24)10-11-31(26,3)30(28)38-22(2)35/h5,23-30,36H,1,6-21H2,2-4H3/q+1/t23-,24+,25-,26-,27-,28-,29-,30-,31-,32-/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H52N2O4
Molecular Weight 528.7663
Charge 0
Count
Stereochemistry EPIMERIC
Additional Stereochemistry No
Defined Stereocenters 10 / 10
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including http://reference.medscape.com/drug/zemuron-rocuronium-343109 | https://www.drugs.com/pro/rocuronium-bromide-injection.html | https://www.drugbank.ca/drugs/DB00728 | https://www.ncbi.nlm.nih.gov/pubmed/2573387 | https://www.ncbi.nlm.nih.gov/pubmed/21568994

Rocuronium (brand names Zemuron, Esmeron) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anesthesia to facilitate endotracheal intubation by providing skeletal muscle relaxation, most commonly required for surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent with a rapid to intermediate onset depending on dose and intermediate duration. It acts by competing for cholinergic receptors at the motor end-plate. This action is antagonized by acetylcholinesterase inhibitors, such as neostigmine and edrophonium. Most common adverse reactions are transient hypotension and hypertension.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
8.6 µM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
ZEMURON

Approved Use

Rocuronium bromide injection is indicated for inpatients and outpatients as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. Rocuronium bromide is a nondepolarizing neuromuscular blocking agent indicated as an adjunct to general anesthesia to facilitate both rapid sequence and routine tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation. (1)

Launch Date

1994
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
1.4 h
0.6 mg/kg single, intravenous
dose: 0.6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.9 h
0.45 mg/kg single, intravenous
dose: 0.45 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: NEWBORN
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
70%
0.6 mg/kg single, intravenous
dose: 0.6 mg/kg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
ROCURONIUM unknown
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (14%)
Vomiting (3%)
Sources:
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (14%)
Vomiting (6%)
Procedural hypotension (5%)
Sources:
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (17%)
Vomiting (8%)
Procedural hypotension (5%)
Nausea (5%)
Sources:
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Other AEs: Procedural pain, Vomiting...
Other AEs:
Procedural pain (18%)
Vomiting (12%)
Procedural hypotension (4%)
Nausea (4%)
Sources:
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Other AEs: Procedural pain, Hypercapnia...
Other AEs:
Procedural pain (12%)
Hypercapnia (3%)
Nausea (3%)
Sources:
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
midazolam(1-2 mg)
propofol(1.8 mg/kg)
alfentanil(9 ug/kg)
Sources:
unhealthy, 33.1
n = 20
Health Status: unhealthy
Condition: surgical procedures
Age Group: 33.1
Sex: F
Population Size: 20
Sources:
Other AEs: Nausea and vomiting...
Other AEs:
Nausea and vomiting (2 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Procedural pain 14%
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Vomiting 3%
0.15 mg/kg single, intravenous
Recommended
Dose: 0.15 mg/kg
Route: intravenous
Route: single
Dose: 0.15 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 64
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 64
Sources:
Procedural pain 14%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Procedural hypotension 5%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Vomiting 6%
0.45 mg/kg single, intravenous
Recommended
Dose: 0.45 mg/kg
Route: intravenous
Route: single
Dose: 0.45 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 63
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 63
Sources:
Procedural pain 17%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Nausea 5%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Procedural hypotension 5%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Vomiting 8%
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 66
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 66
Sources:
Vomiting 12%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural pain 18%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Nausea 4%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural hypotension 4%
1 mg/kg single, intravenous
Recommended
Dose: 1 mg/kg
Route: intravenous
Route: single
Dose: 1 mg/kg
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 56
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 56
Sources:
Procedural pain 12%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Hypercapnia 3%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Nausea 3%
10 ug/kg/min single, intravenous
Recommended
Dose: 10 ug/kg/min
Route: intravenous
Route: single
Dose: 10 ug/kg/min
Co-administed with::
sevoflurane(2-2.5 MAC)
Sources:
unhealthy, 0-17
n = 73
Health Status: unhealthy
Condition: surgical procedures
Age Group: 0-17
Sex: M+F
Population Size: 73
Sources:
Nausea and vomiting 2 patients
0.6 mg/kg single, intravenous
Recommended
Dose: 0.6 mg/kg
Route: intravenous
Route: single
Dose: 0.6 mg/kg
Co-administed with::
midazolam(1-2 mg)
propofol(1.8 mg/kg)
alfentanil(9 ug/kg)
Sources:
unhealthy, 33.1
n = 20
Health Status: unhealthy
Condition: surgical procedures
Age Group: 33.1
Sex: F
Population Size: 20
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG



Drug as perpetrator​

Drug as perpetrator​

Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
likely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
unlikely
yes
PubMed

PubMed

TitleDatePubMed
Choice of the muscle relaxant for rapid-sequence induction.
2001
Choice of the hypnotic and the opioid for rapid-sequence induction.
2001
Muscle relaxants in paediatric day case surgery.
2001
Muscle relaxants suitable for day case surgery.
2001
Comparison of the influence of desflurane nitrous oxide anesthesia to propofol nitrous oxide anesthesia on rocuronium bromide induced neuromuscular block.
2001
Comparative study of the TOF-ratio measured by the ParaGraph versus the TOF-Guard, with and without thumb repositioning.
2001
[Anesthesia in Prader-Willi syndrome for major surgery for kyphoscoliosis].
2001 Aug-Sep
The new neuromuscular blocking agents: do they offer any advantages?
2001 Dec
[New muscle relaxants].
2001 Dec
Why do we still use suxamethonium for caesarean section?
2001 Dec
Propofol anaesthesia via target controlled infusion or manually controlled infusion: effects on the bispectral index as a measure of anaesthetic depth.
2001 Dec
Equi-lasting doses of rocuronium, compared to mivacurium, result in improved neuromuscular blockade in patients undergoing gynecological laparoscopy : [Des doses de durée équivalente de rocuronium, comparé au mivacurium, améliorent la curarisation chez des patientes qui subissent une laparoscopie gynécologique].
2001 Dec
[Sevoflurane augments the degree and speeds the onset of rocuronium evoked neuromuscular blockade in children].
2001 Dec
The effect of rocuronium on intraocular pressure: a comparison with succinylcholine.
2001 Dec
Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients.
2001 Jan
Rocuronium: high risk for anaphylaxis?
2001 May
Rocuronium: high risk for anaphylaxis?
2001 Nov
Rocuronium and anaphylaxis--a statistical challenge.
2001 Nov
Allergic reactions during anaesthesia - increased attention to the problem in Denmark and Norway.
2001 Nov
Rapid sequence induction: a national survey of practice.
2001 Nov
Precurarization and priming: a theoretical analysis of safety and timing.
2001 Nov
Anaphylaxis during anaesthesia. Results of a two-year survey in France.
2001 Oct
Is succinylcholine appropriate or obsolete in the intensive care unit?
2001 Oct
Reexamined: the recommended endotracheal intubating dose for nondepolarizing neuromuscular blockers of rapid onset.
2001 Oct
Probability of acceptable intubation conditions with low dose rocuronium during light sevoflurane anaesthesia in children.
2001 Sep
Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison between female and male patients.
2001 Sep
Target controlled infusion of rocuronium: selection of a pharmacokinetic model.
2002
An isolated, antegrade, perfused, peroneal nerve anterior tibialis muscle model in the rat: a novel model developed to study the factors governing the time course of action of neuromuscular blocking agents.
2002 Apr
Rocuronium pharmacokinetic-pharmacodynamic relationship under stable propofol or isoflurane anesthesia.
2002 Apr
Neuromuscular pharmacology of TAAC3, a new nondepolarizing muscle relaxant with rapid onset and ultrashort duration of action.
2002 Apr
Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships.
2002 Apr 25
Effects of rocuronium pretreatment on muscle enzyme levels following suxamethonium.
2002 Feb
Comparison of rocuronium and suxamethonium for rapid tracheal intubation in children.
2002 Feb
Effect of 17 beta-estradiol-D-17 beta-glucuronide on the rat organic anion transporting polypeptide 2-mediated transport differs depending on substrates.
2002 Feb
Population pharmacodynamic modeling without plasma concentrations of rocuronium in children.
2002 Jan
The detection and identification of quaternary nitrogen muscle relaxants in biological fluids and tissues by ion-trap LC-ESI-MS.
2002 Jan-Feb
Prehospital tracheal intubating conditions during rapid sequence intubation: rocuronium versus vecuronium.
2002 Jan-Feb
2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide.
2002 Jun
Presynaptic inhibitory effects of rocuronium and SZ1677 on [3H]acetylcholine release from the mouse hemidiaphragm preparation.
2002 Jun
Effects of remifentanil and alfentanil on the cardiovascular responses to induction of anaesthesia and tracheal intubation in the elderly.
2002 Mar
The influence of induction technique on intubating conditions 1 min after rocuronium administration: a comparison of a propofol-ephedrine combination and propofol.
2002 Mar
Impact of shorter-acting neuromuscular blocking agents on fast-track recovery of the cardiac surgical patient.
2002 Mar
The Laryngeal Mask Airway ProSeal(TM) as a temporary ventilatory device in grossly and morbidly obese patients before laryngoscope-guided tracheal intubation.
2002 Mar
Prolonged neuromuscular block after rocuronium in postpartum patients.
2002 Mar
The potency of new muscle relaxants on recombinant muscle-type acetylcholine receptors.
2002 Mar
The neuromuscular transmission module versus the relaxometer mechanomyograph for neuromuscular block monitoring.
2002 Mar
Pretreatment before succinylcholine for outpatient anesthesia?
2002 Mar
Mild core hypothermia and anesthetic requirement for loss of responsiveness during propofol anesthesia for craniotomy.
2002 May
The neuropathologic effects in rats and neurometabolic effects in humans of large-dose remifentanil.
2002 May
The hemodynamic effects of rapacuronium in patients with coronary artery disease: succinylcholine and vecuronium compared.
2002 May
Patents

Sample Use Guides

0.45-0.6 mg/kg IV Maintenance: 0.1-0.2 mg/kg IV repeat PRN OR Continuous infusion: 0.01-0.012 mg/kg/min IV
Route of Administration: Intravenous
Aliquots of 100 mkl whole heparinized blood of rocuronium-allergic patients (positive basophil activation test and skin test) were challenged at 37 C with buffer as a negative control, anti-IgE (Pharmingen,BDBioscience, Erembodegem, Belgium) as a positive control, serial dilutions of rocuronium (Esmeron, Organon, Brussels, Belgium, 0.2–2.0 x 10^3 mkg/ml), serial dilutions of sugammadex (Bridion; Merck Sharp & Dohme, Oss, The Netherlands) 0.2–2.0 x 10^3 mkg/ml and with a mixture of different concentrations of rocuronium and sugammadex. Flow cytometric analysis of basophils was performed using triple labelling with CD123-PE, HLA-DR-PerCP, CD63-FITC (BD Biosciences) and using monoclonal antihuman IgE (clone GE-1; Sigma-Aldrich Chemic GmBH, Steinheim, Germany), labelled with AlexaFluor 488 (Molecular Probes, Invitrogen, Paisley, UK). Samples were analysed on a flow cytometer (FACsCanto BD; Immunocytometry Systems, San Jose, CA, USA) and expressed as CD63-positive basophils. Samples were regarded as positive when CD63-reactive basophils were higher than 4%
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:44:19 GMT 2023
Edited
by admin
on Fri Dec 15 15:44:19 GMT 2023
Record UNII
WRE554RFEZ
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
ROCURONIUM
MI   WHO-DD  
Common Name English
ROCURONIUM ION
Common Name English
ROCURONIUM [MI]
Common Name English
Rocuronium [WHO-DD]
Common Name English
PYRROLIDINIUM, 1-((2.BETA.,3.ALPHA.,5.ALPHA.,16.BETA.,17.BETA.)-17-(ACETYLOXY)-3-HYDROXY-2-(4-MORPHOLINYL)ANDROSTAN-16-YL)-1-(2-PROPENYL)-
Systematic Name English
ROCURONIUM CATION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C66886
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
NDF-RT N0000175732
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
NDF-RT N0000175720
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
WHO-ATC M03AC09
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
Code System Code Type Description
SMS_ID
100000084941
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
NCI_THESAURUS
C80999
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
PUBCHEM
441290
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
LACTMED
Rocuronium
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
DRUG BANK
DB00728
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
DAILYMED
WRE554RFEZ
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
RXCUI
68139
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY RxNorm
WIKIPEDIA
Rocuronium
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
DRUG CENTRAL
2396
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
EVMPD
SUB04260MIG
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
MESH
C061870
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
CAS
143558-00-3
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
MERCK INDEX
m9645
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY Merck Index
IUPHAR
4003
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
EPA CompTox
DTXSID6048339
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
FDA UNII
WRE554RFEZ
Created by admin on Fri Dec 15 15:44:19 GMT 2023 , Edited by admin on Fri Dec 15 15:44:19 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
BINDER->LIGAND
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE -> PARENT
17-desacetyl-rocuronium has been found in negligible amounts
MINOR
URINE
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC